Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

NCT07629596 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Autoimmune Hemolytic Anemia (AIHA)

Interventions

DRUG: Arnovie101 Infusion Intravenous

Sponsor

Circunited BioPharma (Shenzhen) Co., Ltd.

Collaborators

[object Object]